Int J Cardiol:先天性心脏病手术患儿B型利钠肽前体N末端水平的变化及临床预后

2019-02-16 xing.T 网络

由此可见,升高的NT-proBNP可能是接受心脏手术的冠心病患儿不良预后的有用标志。

近日,血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,该研究旨在探讨先天性心脏病(CHD)手术后B型利钠肽前体N末端(NT-proBNP)变化与患者预后的关系。

在心脏手术之前和之后的1、12、36和72小时测量了873名儿童的NT-proBNP水平。患者在术后30、90和180天进行随访。感兴趣的临床结局包括长期重症监护病房(ICU)停留(>3天)、机械通气时间延长(>48h)和不良事件发生(即死亡、再入院和感染)。

手术后NT-proBNP增加,12h达到峰值,之后逐渐下降。NT-proBNP中位数变化(即术前减去术后72小时水平)为-1212.68pg/mL(四分位数范围为-3099.87至-66.81)。29.4%的患者发生不良事件。多因素logistic回归分析显示,较低的体表面积(BSA)、较高的先天性心脏手术风险调整-1评分和较小的年龄与长期ICU住院和机械通气的风险增加显著相关。NT-proBNP的减少或轻微增加与较低的风险相关。在多变量cox回归中,NT-proBNP的减少或轻微增加与较低的死亡风险相关。除了NT-proBNP变化的四分位数外,BSA还是不良事件的重要预测因子。根据受限制的三次样条模型,延长ICU停留和机械通气的关联是U形的。NT-proBNP变化与死亡之间的关联尚无定论。

由此可见,升高的NT-proBNP可能是接受心脏手术的冠心病患儿不良预后的有用标志。

原始出处:

Ramit KumarGupta,et al.Change in N-terminal pro B-type natriuretic peptide levels and clinical outcomes in children undergoing congenital heart surgery.International Journal of Cardiology.2019.https://www.sciencedirect.com/science/article/pii/S0167527318354032

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-18 huirong
  6. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1782006, encodeId=b40f1e8200627, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 05 09:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777187, encodeId=86ea1e7718718, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Wed Nov 06 11:54:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780486, encodeId=b0171e8048616, content=<a href='/topic/show?id=9f61381845' target=_blank style='color:#2F92EE;'>#B型利钠肽前体N末端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3818, encryptionId=9f61381845, topicName=B型利钠肽前体N末端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Sun Apr 07 10:54:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366479, encodeId=a36e13664e959, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369429, encodeId=772013694294f, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534734, encodeId=726f1534e34d5, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Mon Feb 18 01:54:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360776, encodeId=e268360e76a9, content=好文章,点赞啦!认真学习,谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Feb 16 10:59:55 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-16 ylzr123

    好文章,点赞啦!认真学习,谢谢分享给广大同好!

    0

相关资讯

JAHA:小儿先天性心脏病手术后的死亡率

先天性心脏病手术幸存者面临着过早死亡的长期风险,这主要与残余CHD疾病、心衰和心律失常有关,也和其他非心脏疾病有关。

JACC:使用爱德华兹Sapien瓣膜的经导管肺动脉瓣植入术

肺部使用爱德华兹Sapien瓣膜的早期结果表明手术的成功率很高。

2018 科隆共识会议建议:成人先天性心脏病患者肺动脉高压

2018年克隆会议上发布了关于成人先天性心脏病患者肺动脉高压管理建议,内容主要涉及肺动脉高压的定义,分类,先天性心脏病患者肺动脉高压的诊断,危险分层以及随访、治疗等内容。

Heart:心力衰竭住院治疗预测先天性心脏病相关肺动脉高压患者的死亡率

由此可见,PH-ACHD患者发生长期并发症很常见。HF住院治疗可预测死亡,并应考虑该人群的危险分层。

Heart:英国先天性心脏病患者的心脏或心肺移植

虽然预计CHD患者的移植会增多,但英国的实际数字似乎滞后于晚期心衰CHD患者的增多。

JAHA:家庭社会经济状况对严重先天性心脏病患儿健康相关生活质量的影响

对于严重先天性心脏病患儿,家庭SES是与HRQOL相关的重要因素。